Dr. Chen is a Professor and Founder Chairman in the Department of Neurosurgery/Neuro-oncology of Sun Yat-sen University Cancer Center. Dr. Chen is Founder president of Chinese Society of Neuro-Oncology(CSNO). Dr. Chen’s clinical interests include microsurgery and multimodality treatment for primary and metastatic tumors in central nervous system, particularly gliomas. Chemotherapy and immunotherapy are important adjuvant treatments in his clinical practice. 

Dr. Chen has received many awards including Francis McNaughton Memorial Prize in 1998(Canadian Neurological Society), WHO Prize for Chinese Young Professional in Mental Health & Neuroscience in 1993, and Wang Chong-cheng Academic Award for Chinese Neurosurgeon in 2006.

More than 100 peer-reviewed papers have been published in leading scientific journals including Cancer Research, Clinical Cancer Research, Journal of National Cancer Institute, Neurosurgery, Journal of Neurosurgery, Journal of Neuro-oncology, and Neuro-oncology. 

Dr. Chen’s research interests including: Genetic alterations leading to resistance of human brain tumors to chemotherapy, and has found that ERCC2, one of the important components in nucleotide excision repair (NER) system related to alkylating agent resistance in human tumor cell lines. MGMT associated drug resistance in glioma has also been investigated and applied in his clinical practice. He also, for the first time, has found that vasculogenic mimicry (VM), a new circulation exists in malignant gliomas. And, immunotherapy for glioma, such as CIK cell local therapy and DC-glioma fusion cells (FC), is also his investigating field. Last 20 years, Dr. Chen has also participated more than 20 clinical trials for glioma treatment as PI, Co-PI or investigator.

For information on Professor Chen's laboratory, click here and select: Brain cancer genetic resistance/drug resistance in glioma/vasculogenic mimicry (VM) in glioma

MD (1982) Suzhou Medical College, Suzhou, China.

Selected Publications

1. Shaoyan Xi, haiping cai, Jiabin Lu, Yu Zhang, yanjiao Yu, Furong Chen, Qitao Huang, and Fang Wang, Zhongping Chen. The pseudogene PRELID1P6 promotes glioma progression via the hnHNPH1-Akt/mTOR axis. Oncogene, published on line:09 June 2021. 

2. Xin Mei, Yin-Sheng Chen, Qing-Ping Zhang, Fu-Rong Chen, Shao-Yan Xi, Ya-Kang Long, Ji Zhang, Hai-Ping Cai, Chao Ke, Jing Wang, Zhong-Ping Chen. Association between glioblastoma cell-derived vessels and poor prognosis of the patients. Cancer Communications. 2020;40:211–221.

3. Xiang-Rong Ni, Yi-Ying Zhao, Hai-Ping Cai, Zhi-Hui Yu, Jing Wang, Fu-Rong Chen, Yan-Jiao Yu, Guo-Kai Feng, Zhong-Ping Chen. Transferrin Receptor 1 Targeted Optical Imaging for Identifying Glioma Margin in Mouse Models. J Neurooncol. 2020，148：245–258.

4. Haiping Cai， Yanjiao Yu，Xiangrong Ni, Cong Li，Yuanjun Hu, Jing Wang, Furong Chen, Shaoyan Xi and Zhongping Chen. LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis. Cell Death and Disease (2020) 11:1032.

5. Hai-ping Cai, Jing Wang, Shao-yan Xi, Xiang-rong Ni, Yin-sheng Chen, Yan-jiao Yu, Zi-wen Cen, Zhi-hui Yu, Fu-rong Chen, Cheng-cheng Guo, Ji Zhang, Chao Ke, Jian Wang and Zhong-ping Chen. Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2/MMP9 in glioma. Cell Death Dis. 2019 Dec; 10(12): 879.IF5.959

6. Mei X, Chen YS, Chen FR, Xi SY, Chen ZP. Glioblastoma stem cell differentiation into endothelial cells evidenced through live cell imaging Running title: Live cell imaging of GSCs CD34 expression. Neuro Oncol. 2017 Mar 8. doi: 10.1093/neuonc/nox016. [Epub ahead of print], Neuro Oncol. 2017 Aug 1;19(8):1109-1118

7. Fu J, Yang QY, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL, Chen ZP.TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. Neuro-oncology, 2013,15（10）：1353-1365

8. Liu XM,Zhang QP,Mu YG,Zhang XH,Sai K,Pang JC,Ng HK,Chen ZP.Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol,2011,(105 ):173-179.

9. Fu J,Shao CJ,Chen FR,NG HK,Chen ZP.Autophagy Induced by Valproic Acid is Associated with Oxidative Stress in Glioma Cell Lines.Neuro-oncology,2010,12(4):328-340.

10. Chen HY,Shao CJ,Chen FR,Kwan AL,Chen ZP.Role of ERCC1 Promoter Hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer,2010,126(8):1255-1259.

11. Yue WY,Yu SH, Zhao SG,Chen ZP. Molecular markers relating to malignant progression in grade II astrocytoma. J Neurosurgery,2009,110(4):709-14.

12. Shao CJ,Fu J,Shi HL,Mu YG,Chen ZP.Activities of DNA-PK and Ku86, but not Ku70, may predictsensitivity to cisplatin in human gliomas.J Neurooncol,2008,89(1):27-35.

13. Chen HY,Shao CJ,Shi HL,Mu YG,Sai K,Chen ZP.Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human gliomas.J Neuro-oncology,2007,82:257-262.

14. Yue WY,Chen ZP.Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem.2005, 53(8):997-1002.

15. Chen ZP,Pan J,Huang Q,Sun ZF,Zhou LY,Wang AD.Antitumor efficacy of SarCNU in a Human Glioma Xenograft Model expressing both MGMT and Extraneuronal Monoamine Transporter.J Neuro-Oncology,2001,51:19-24.

16. Chen ZP,Carter CA,Alley MC,Mohr G,Panasci LC.Both Extraneuronal Monoamine Transporter and O6-methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of SarCNU in Human Tumor Xenografts.J Pharmacol Exp Ther,2001,296(3):712-715.

17. Wang ZM,Chen ZP,Xu ZY,Christodoulopoulos G,Bello V,Mohr G,Aloyz R,Panasci LC.In vitro evidence for homologous recombinational repair in resistance to melphalan.J Natl Cancer Inst,2001,93(19):1473-1478.

18. Chen ZP,Wang G,Huang Q,Sun ZF,Zhou LY,Wang AD,Panasci LC.Enhanced antitumor activity of SarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J Neuro-Oncology,1999,44:7-14.

19. Chen ZP,Remack J,Brent TP,Mohr G,Panasci LC.Extraneuronal Monoamine Transporter Expression vis-à-vis SauCNU Cytotoxicity in Human Tumor Cell Lines.Clinical Cancer Research, 1999,5:4186-4190.

20. Chen ZP,McQuillan A,Mohr G,Panasci LC.Excision repair cross-complementing rodent repair dificiency gene2 expression and chloroethylnitrosourea  resistance in human glioma cell lines. Neurosurgery,1998,42(5)1112-1119.

21. Chen ZP,Malapetsa A,McQuillan A,Marcantonia D,Bello V,Mohr G,Remack J,Brent TP,Panasci LC.Evidence for nucleotide excision repair as a modifying factor of MGMT mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Molecular Pharmacology,1997,52: 815-820. 

22. Chen ZP,Malapetsa A,Marcantonio D,Mohr G,Brien S,Panasci LC.Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Research ,1996,56: 2475-2478.

23. Chen ZP,Malapetsa A,Brien S,Mohr G,Panasci LC.Quantitation of ERCC-2 expression by reverse-transcription polymerase chain reaction comparison to Northern blot analysis. Anal Biochem,1997,244: 50-54.

Updated November 2021 by International Office, Sun Yat-sen University Cancer Center